Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
复制标题
DOI：
10.3390/cancers3032904
复制
发表时间：
2011-07-18
期刊：
影响因子：
5.2
通讯作者：
Van der Bruggen P
中科院分区：
文献类型：
--
作者：
Wieërs G;Demotte N;Godelaine D;Van der Bruggen P
人类肿瘤通常不会被免疫系统自发消除，给癌症患者接种特定抗原的治疗性疫苗后，只有一小部分患者的肿瘤消退。疫苗接种效果差的原因可能是免疫抑制的肿瘤微环境。由于渗入肿瘤转移的T细胞的杀伤靶细胞或分泌细胞因子的能力受损，许多研究人员正试图破译潜在的免疫抑制机制。我们将在这里对这些进行综述，特别是那些被认为是潜在治疗靶点的。将特别关注Galectins，这是一种碳水化合物结合蛋白家族。这些凝集素经常与炎症和癌症有关，并可能成为开发新的抗癌疗法的有用靶点。
Human tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies.